News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Daily News AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More Shelley Wood December 17, 2020
News Conference News AHA 2020 Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials Michael O'Riordan November 17, 2020
News Conference News AHA 2020 Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF Todd Neale November 16, 2020
News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Daily News FDA Clears Dapagliflozin for Heart Failure With Reduced Ejection Fraction Shelley Wood May 06, 2020
News Conference News ACC 2020 A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA Michael O'Riordan March 28, 2020
News Daily News LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure Shelley Wood March 10, 2020
News Features Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses Shelley Wood December 23, 2019
News Features Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019 Todd Neale December 10, 2019
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019
News Conference News AHA 2019 AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials Shelley Wood November 11, 2019
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2019 Todd Neale October 31, 2019
News Daily News Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes L.A. McKeown October 21, 2019
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019